Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low - Should You Sell?

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $13.92 and last traded at $13.92, with a volume of 57467 shares trading hands. The stock had previously closed at $14.12.

Wall Street Analyst Weigh In

Several research analysts have issued reports on DNLI shares. Bank of America dropped their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Stifel Nicolaus upgraded shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price on the stock in a report on Monday, December 16th. Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. HC Wainwright increased their price objective on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. cut their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Denali Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $37.20.

Remove Ads

Denali Therapeutics Stock Performance

The company's fifty day moving average is $19.05 and its two-hundred day moving average is $23.23. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -5.36 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now directly owns 107,976 shares of the company's stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 in the last quarter. Corporate insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new stake in shares of Denali Therapeutics during the third quarter worth $73,000. The Manufacturers Life Insurance Company boosted its position in Denali Therapeutics by 20.0% during the third quarter. The Manufacturers Life Insurance Company now owns 206,819 shares of the company's stock valued at $6,025,000 after purchasing an additional 34,538 shares during the last quarter. FMR LLC raised its position in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Denali Therapeutics by 230.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,625 shares of the company's stock valued at $805,000 after purchasing an additional 19,259 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Denali Therapeutics by 12.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,719 shares of the company's stock worth $866,000 after acquiring an additional 3,316 shares during the period. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.